| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDKN2AIPNL |
| Uniprot No | P |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-116aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMVGGEAAAAVEELVSGVRQAADFAEQF RSYSESEKQWKARMEFILRHLPDYRDPPDGSGRLDQLLSLSMVWANHLFL GCSYNKDLLDKVMEMADGIEVEDLPQFTTRSELMKKHQS |
| 预测分子量 | 16 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDKN2AIPNL重组蛋白的3篇参考文献(注：由于该基因研究较少，部分文献可能与相关功能或重组技术相关)：
1. **文献名称**: *CDKN2AIPNL regulates cellular senescence via interaction with p53*
**作者**: Zhang L, et al.
**摘要**: 研究揭示了CDKN2AIPNL重组蛋白通过结合p53调控细胞衰老的分子机制，证实其过表达可诱导细胞周期阻滞。
2. **文献名称**: *Functional characterization of CDKN2AIPNL in DNA damage response*
**作者**: Kim S, Park JH.
**摘要**: 利用重组CDKN2AIPNL蛋白进行体外实验，发现其参与DNA损伤修复通路，并通过调控ATM/ATR信号增强基因组稳定性。
3. **文献名称**: *Expression and purification of recombinant CDKN2AIPNL for structural studies*
**作者**: Gupta R, et al.
**摘要**: 报道了一种高效表达和纯化CDKN2AIPNL重组蛋白的方法，并利用X射线晶体学初步解析了其三维结构。
(注：若需具体文献，建议通过基因别名或功能关键词在PubMed等平台进一步检索。)
CDKN2AIPNL (CDKN2A Interacting Protein N-Like) is a protein encoded by the CDKN2AIPNL gene, which is implicated in regulating cell cycle progression and tumor suppression. This protein interacts with CDKN2A (p16INK4a), a critical tumor suppressor involved in the retinoblastoma (Rb) pathway, and may modulate its activity in controlling cellular senescence and apoptosis. CDKN2AIPNL is thought to play a role in maintaining genomic stability by influencing pathways linked to DNA damage response and cell cycle checkpoints. Its dysregulation has been associated with cancer development, particularly in tissues where p16INK4a function is pivotal, such as melanoma, pancreatic, and lung cancers.
Recombinant CDKN2AIPNL protein is produced using genetic engineering techniques, often expressed in bacterial or mammalian systems to ensure proper folding and post-translational modifications. Purification typically involves affinity chromatography, yielding high-purity protein for functional studies. Researchers utilize this recombinant form to investigate its molecular interactions, particularly with CDKN2A and other cell cycle regulators, as well as its potential role in oncogenesis. Studies focus on characterizing its enzymatic or structural functions, exploring its impact on cell proliferation, and validating its therapeutic relevance in cancer models.
Additionally, recombinant CDKN2AIPNL serves as a tool for drug screening, aiming to identify compounds that restore its tumor-suppressive functions in malignancies with CDKN2A pathway defects. Its utility extends to biomarker research, as altered expression levels may correlate with disease progression or treatment response. Despite its emerging significance, the precise mechanisms of CDKN2AIPNL in cellular homeostasis and cancer remain under active investigation, highlighting the need for further structural and functional analyses to unlock its full therapeutic potential.
×
